Topical therapy for psoriasis.
Lebwohl
M
M
Department of Dermatology, Mt. Sinai School of Medicine, New York, New York, USA.
Abel
E
E
Zanolli
M
M
Koo
J
J
Drake
L
L
D000279:Administration, Cutaneous; D000287:Administration, Topical; D000875:Anthralin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002762:Cholecalciferol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005938:Glucocorticoids; D006801:Humans; D011701:PUVA Therapy / Q000009:adverse effects / Q000379:methods; D011565:Psoriasis / Q000188:drug therapy*; D013638:Tars / Q000009:adverse effects / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D005938:Glucocorticoids; D013638:Tars; D002762:Cholecalciferol; D000875:Anthralin